Castle Creek Biosciences develops novel gene therapies to improve lives. The company focuses on cell and gene therapy for patients and families.

Castle Creek Biosciences

Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, 
D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).

Horizon Technology Finance

U.S. Food and Drug Administration

Fidelity Management and Research Company

Valor Equity Partners

Paragon Biosciences

Castle Creek Biosciences, Inc.

The earliest description of what is now known as epidermolysis bullosa (EB) was by Austrian dermatologist Ferdinand Ritter von Hebra in 1870. It’s been 154 years and still there are very limited treatment options and no cures for EB. 

One out of every 20,000 U.S. births, or approximately 200 children yearly, are born with EB. This painful disorder requires a lifetime of daily wound care along with a variety of medical specialists. Those with severe forms of EB usually do not survive past 35 years of age. 

At Castle Creek, we hope our work can one day deliver relief to the people living with EB and their families.

What an incredible four days our team had at the debra of America Care Conference in Atlanta! 

We appreciate everyone who connected with us to share their stories about how epidermolysis bullosa (EB) has impacted their lives. 

Special shout out to our CEO Matthew Gantz for his presentation on our upcoming phase 3 clinical trial. 

#dcc2024 #debracareconference #epidermolysisbullosa

Our CEO, Matthew Gantz, is heading to Atlanta for the debra of America Care Conference, an annual event where people living with epidermolysis bullosa and their families gather for knowledge sharing in a nurturing and supportive environment. 

On July 30, Matt will be sharing an update on Castle Creek’s preparations for a phase 3 clinical trial for a potential treatment for dystrophic epidermolysis bullosa (DEB).  Hope to see you there!

https://lnkd.in/ghMU3QnQ

We’re proud to be a Platinum Sponsor of the upcoming debra of America Care Conference! Our work is fueled by people living with epidermolysis bullosa, who experience a lifetime of challenges that no one should ever have to go through.

Recently, Castle Creek hosted Michelle and Marley, two people living with Epidermolysis Bullosa (EB). 

Michelle shared her story of growing up with EB and how she navigates her day as an adult living with EB.  

Nine-year-old Marley and his mother, Shauna, have just begun their journey into advocacy activities. The room was filled with the warmth of Marley’s smile and his big personality connected with the crowd while Shauna talked to the CCB team. 

These first-hand stories of Michelle and Marley really hit home. Their stories, among the thousands of others, are what fuel our work at Castle Creek. 

We know that a person with EB has to overcome numerous challenges every single day. Simple tasks like bathing and eating can take hours, and that’s just the beginning. 

While there is no cure for EB, we are hopeful that our work can one day help provide relief for those living with this painful condition. 

Learn more about Michelle’s life with EB here: https://lnkd.in/gjFFdYHY

On National Doctors' Day, we celebrate the invaluable contributions doctors  make to healthcare and the critical role they play in healing and saving lives.

Today, we remember the impact of Dr. Martin Luther King, Jr. who called for unity and understanding, to create a world where everyone has the opportunity to flourish. #martinlutherkingjr

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 31, 2024 2:14 AM	a1dfd56d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 31, 2024 2:14 AM	b12cdb11
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 2:14 AM	816f372a
news basic	general	Aug 31, 2024 2:14 AM	31b37bf7
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CAST

COM:CASTLECREEKBIO

Castle Creek Biosciences